Virus-specific cells, CD8 +T, appear to deplete during chronic viral infection, according to research published online by "Nature" magazine on August 3.
However, the cells are able to control viral replication in both animal models and HIV infection, according to the research findings.
Researchers found a unique subset that offer higher anti- viral potential than previously known, thus, showing greater therapeutic potential.
The research was led by the Third Military Medical University in Chongqing Municipality, with a number of partner institutions. It began in early 2013 with government financial support.
"Through certain means, to increase and stabilise the type of cells can strengthen their virus-purging ability, thus, providing new possibilities for cures," Ye Lilin, co-author of the paper and professor at the Third Military Medical University, told Xinhua today.
Current therapies can only contain the viral replication, but cannot purge them completely in chronic diseases like HIV.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
